A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia

PLoS Neglected Tropical Diseases

Volumn 12, Issue 7, 2018, Pages

  López, Liliana ^a   Vélez, Iván ^a   Asela, Claudia ^a   Cruz, Claudia ^b   Alves, Fabiana ^c   Robledo, Sara ^a   Arana, Byron ^c  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b DISAN   (Colombia)

^c Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; ANFOLEISH; LIVER ENZYME; MEGLUMINE ANTIMONATE; ANTIPROTOZOAL AGENT; SKIN CREAM;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; BURNING SENSATION; CALCULATION; CLINICAL EVALUATION; COLOMBIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EPITHELIZATION; EVIDENCE BASED MEDICINE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCIDENCE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRURITUS; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; RASH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SAMPLE SIZE; SKIN DEFECT; SKIN LEISHMANIASIS; SKIN ULCER; TOXICITY TESTING; ULCERATIVE COLITIS; ULTRAVIOLET IRRADIATION; YOUNG ADULT; CLINICAL TRIAL; DRUG EFFECT; GENETICS; LEISHMANIA; PARASITOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; COLOMBIA; FEMALE; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; SKIN CREAM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85051295615     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0006653     Document Type: Article

References (26)

1. World Health Organization (WHO) (2010) Control of the leishmaniasis. 202 p.
2. de Vries HJ, Reedijk SH, Schallig HD, (2015) Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol16: 99–109. doi: 10.1007/s40257-015-0114-z pmid: 25687688
3. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis. Lancet Infect Dis7: 581–596. doi: 10.1016/S1473-3099(07)70209-8 pmid: 17714672
4. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One7: e35671. doi: 10.1371/journal.pone.0035671 pmid: 22693548
5. Silva NS, Muniz VD, (2009) [Epidemiology of American tegumentary leishmaniasis in the State of Acre, Brazilian Amazon]. Cad Saude Publica25: 1325–1336. pmid: 19503963
6. Velez ID, Carrillo LM, Lopez L, Rodriguez E, Robledo SM, (2012) An epidemic outbreak of canine cutaneous leishmaniasis in Colombia caused by Leishmania braziliensis and Leishmania panamensis. Am J Trop Med Hyg86: 807–811. doi: 10.4269/ajtmh.2012.11-0408 pmid: 22556078
7. Cardona-Arias JA, Lopez-Carvajal L, Tamayo Plata MP, Dario-Velez I, (2017) Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis. J Evid Based Med.
8. Martinez S, Marr JJ, (1992) Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med326: 741–744. doi: 10.1056/NEJM199203123261105 pmid: 1738379
9. Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee M, Famili S, et al. (2011) Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. Dermatol Res Pract2011: 269515. doi: 10.1155/2011/269515 pmid: 21747837
10. Lopez-Jaramillo P, Rincon MY, Garcia RG, Silva SY, Smith E, et al. (2010) A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis. Am J Trop Med Hyg83: 97–101. doi: 10.4269/ajtmh.2010.09-0287 pmid: 20595484
11. Velez I, Lopez L, Sanchez X, Mestra L, Rojas C, et al. (2010) Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg83: 351–356. doi: 10.4269/ajtmh.2010.10-0060 pmid: 20682881
12. Copeland NK, Aronson NE, (2015) Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis28: 426–437. doi: 10.1097/QCO.0000000000000194 pmid: 26312442
13. Lee SA, Hasbun R, (2003) Therapy of cutaneous leishmaniasis. Int J Infect Dis7: 86–93. pmid: 12839708
14. Murray HW, (2012) Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg86: 434–440. doi: 10.4269/ajtmh.2012.11-0682 pmid: 22403313
15. Neves LO, Talhari AC, Gadelha EP, Silva Junior RM, Guerra JA, et al. (2011) A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol86: 1092–1101. pmid: 22281895
16. Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, et al. (2011) Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol25: 973–977. doi: 10.1111/j.1468-3083.2010.03908.x pmid: 21129042
17. Solomon M, Pavlotzky F, Barzilai A, Schwartz E, (2013) Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol68: 284–289. doi: 10.1016/j.jaad.2012.06.014 pmid: 22858005
18. Lecoeur H, Buffet P, Morizot G, Goyard S, Guigon G, et al. (2007) Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model. PLoS Negl Trop Dis1: e34. doi: 10.1371/journal.pntd.0000034 pmid: 18060082
19. Montalvo AM, Fraga J, Tirado D, Blandon G, Alba A, et al. (2017) Detection and identification of Leishmania spp.: application of two hsp70-based PCR-RFLP protocols to clinical samples from the New World. Parasitol Res116: 1843–1848. doi: 10.1007/s00436-017-5454-6 pmid: 28573463
20. Montalvo AM, Fraga J, Maes I, Dujardin JC, Van der Auwera G, (2012) Three new sensitive and specific heat-shock protein 70 PCRs for global Leishmania species identification. Eur J Clin Microbiol Infect Dis31: 1453–1461. doi: 10.1007/s10096-011-1463-z pmid: 22083340
21. Ramirez JR, Agudelo S, Muskus C, Alzate JF, Berberich C, et al. (2000) Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis. J Clin Microbiol38: 3768–3773. pmid: 11015400
22. Perez AP, Altube MJ, Schilrreff P, Apezteguia G, Celes FS, et al. (2016) Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro. Colloids Surf B Biointerfaces139: 190–198. doi: 10.1016/j.colsurfb.2015.12.003 pmid: 26709977
23. Butani D, Yewale C, Misra A, (2016) Topical Amphotericin B solid lipid nanoparticles: Design and development. Colloids Surf B Biointerfaces139: 17–24. doi: 10.1016/j.colsurfb.2015.07.032 pmid: 26700229
24. Fang JY, Fang CL, Liu CH, Su YH, (2008) Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm70: 633–640. doi: 10.1016/j.ejpb.2008.05.008 pmid: 18577447
25. Gutierrez V, Seabra AB, Reguera RM, Khandare J, Calderon M, (2016) New approaches from nanomedicine for treating leishmaniasis. Chem Soc Rev45: 152–168. doi: 10.1039/c5cs00674k pmid: 26487097
26. Cota GF, de Sousa MR, Fereguetti TO, Saleme PS, Alvarisa TK, et al. (2016) The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-Analysis. PLoS One11: e0149697. doi: 10.1371/journal.pone.0149697 pmid: 26894430